➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKinsey
Colorcon
Moodys
Express Scripts

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Patent: 9,663,523

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,663,523
Title:BET protein-inhibiting 5-aryltriazoleazepines
Abstract: The present invention relates to BET-protein-inhibitory, in particular BRD4-inhibitory 5-aryltriazoloazepines of the general formula (I) ##STR00001## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meanings given for the general formula (I), to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for neoplastic disorders. The present invention further relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammatory diseases, in atherosclerotic disorders and in male fertility control.
Inventor(s): Schmees; Norbert (Berlin, DE), Kuhnke; Joachim (Potsdam, DE), Haendler; Bernard (Berlin, DE), Neuhaus; Roland (Berlin, DE), Lejeune; Pascale (Berlin, DE), Siegel; Stephan (Berlin, DE), Kruger; Martin (Berlin, DE), Fernandez-Montalvan; Amaury Ernesto (Berlin, DE), Kunzer; Hermann (Berlin, DE), Gallenkamp; Daniel (Wuppertal, DE)
Assignee: BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)
Application Number:14/432,158
Patent Claims:see list of patent claims

Details for Patent 9,663,523

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) 2032-09-28 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) 2032-09-28 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) 2032-09-28 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) 2032-09-28 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) 2032-09-28 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Merck
Medtronic
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.